Neuralink Staff Prepare to Cash In on Soaring Valuation

Employees at Elon Musk's Neuralink are preparing to sell company stock due to a valuation boost after its first human trial. The company may launch a tender offer soon to buy back shares from staff. This scarcity strategy in Musk's companies, including SpaceX and xAI, has made shares highly sought after.

Some staff at Elon Musk's Neuralink are gearing up to sell their stock following a significant increase in the company's valuation after its first human trial, sources familiar with the matter reported.

Neuralink's stock compensation is a major driver for employees at the startup, though selling these shares without company approval typically involves complex transactions on niche private market exchanges. The company is expected to launch a tender offer to buy back shares from staff, possibly as early as next month, according to insider sources.

The valuation jump coincides with the company's first successful human trial, showing a rise in value to as much as $8 billion—a sharp increase from last year. While Neuralink and Musk did not comment, this trend reflects ongoing market trades which suggest an upward valuation trajectory.

(With inputs from agencies.)